16 results on '"Chien, R."'
Search Results
2. FRI-328 - Every-two-week ropegienterferon alfa-2b is safe with higher hepatitis B e antigen seroconversion rate in interferon naive patients with chronic hepatitis B infection: A phase 2, open label, randomized, active control, dose finding study
3. PS-158 - Increased incidence of HBsAg seroclearance in HBeAg negative chronic hepatitis B patients discontinued Nuc therapy comparing to natural course-a propensity score matched study
4. PS-098 - Ledipasvir/sofosbuvir for 12 weeks is safe and effective in patients with chronic hepatitis C and hepatitis B coinfection: A phase 3 study in Taiwan
5. FRI-109 - UGT2B28 Genomic Variation is Associated with Hepatitis B E-Antigen Seroconversion in Response to Entecavir or Peginterferon Therapy
6. P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study
7. P0809 : 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study
8. P669 A GENOME-WIDE ASSOCIATION STUDY ON PERSISTENT HBV INFECTION AND ITS CLINICAL SIGNIFICANCE IN MALE HAN-TAIWANESE
9. O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
10. 758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT
11. 521 HEPATOCELLULAR CARCINOMA DEVELOPMENT IN HBe-NEGATIVE HEPATITIS B CIRRHOTIC PATIENTS WITH ENTECAVIR TREATMENT
12. Selective ion extraction for high throughput screening with a microfluidic enzyme assay.
13. PCN57 ECONOMICS OF A MULTI-GENE ASSAY TO PREDICT RECURRENCE OF EARLY STAGE BREAST CANCER: EXPERIENCE OF A LARGE UNITED STATES INSURANCE PROGRAM
14. P201 Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score® in clinical practice.
15. P215A Cost–benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore.
16. 5161 POSTER Decision Impact and Economic Evaluation of the 21-gene Recurrence Score (RS) Assay for Physicians and Patients in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.